Pål Gunnar Larsson

Pål Gunnar Larsson

Auto-generated profile, based on publicly available information

Pål Gunnar Larsson

Department of Neurosurgery, University of Oslo Medical Center

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
JKJulia W. Y. Kam
Julia W. Y. Kam
JLJack J. Lin
Jack J. Lin
ASAnne-Kristin Solbakk
Anne-Kristin Solbakk
TETor Endestad
Tor Endestad
PLPål G. Larsson
Pål G. Larsson
RKRobert T. Knight
Robert T. Knight

21 December 2021 in Epilepsia
Verified
Journal Article
Open access
PDF file
KKKonstantin H. Kostov
Konstantin H. Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
CEChristian Alexander Cornelius Eckmann
Christian Alexander Cornelius Eckmann
JPJukka Peltola
Jukka Peltola
Objective: This study was undertaken to evaluate the efficacy of vagus nerve stimulation (VNS) over time, and to determine which patient groups derive the most benefit.Methods: Long‐term outcomes are reported in 436 epilepsy patients from a VNS quality registry (52.8% adults, 47.2% children), with a median follow‐up of 75 months. Patients were stratified according to evolution of response into constant responders, fluctuating responders, and nonresponders. The effect was evaluated at 6, 12, 24, 36, and 60 months. Multivariate regression analysis was used to identify predictors of response.Results: The cumulative probability of ≥50% seizure reduction was 60%; however, 15% of patients showed a fluctuating course. Of those becoming responders, 89.5% (230/257) did so within 2 years. A steady increase in effect was observed among constant responders, with 48.7% (19/39) of those becoming seizure‐free and 29.3% (39/133) with ≥75% seizure reduction achieving these effects within 2–5 years. Some effect (25%–<50%) at 6 months was a positive predictor of becoming a responder (odds ratio [OR] = 10.18, p < .0001) and having ≥75% reduction at 2 years (OR = 3.34, p = .03). Patients without intellectual disability had ORs of 3.34 and 3.11 of having ≥75% reduction at 2 and 5 years, respectively, and an OR of 6.22 of being seizure‐free at last observation. Patients with unchanged antiseizure medication over the observation period showed better responder rates at 2 (63.0% vs. 43.1%, p = .002) and 5 years (63.4% vs. 46.3%, p = .031) than patients whose antiseizure medication was modified. Responder rates were higher for posttraumatic (70.6%, p = .048) and poststroke epilepsies (75.0%, p = .05) than other etiologies (46.5%).Significance: Our data indicate that the effect of VNS increases over time and that there are important clinical decision points at 6 and 24 months for evaluating and adjusting the treatment. There should be better selection of candidates, as certain patient groups and epilepsy etiologies respond more favorably.

1 May 2019 in Clinical Neurophysiology
Verified
Journal Article
Closed access
BMBrian E. Mouthaan
Brian E. Mouthaan
MRMatea Rados
Matea Rados
PBPaul Boon
Paul Boon
ECEvelien Carrette
Evelien Carrette
BDBeate Diehl
Beate Diehl
KBKees P.J. Braun
Kees P.J. Braun

3 July 2023 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
JWJan Weber
Jan Weber
GIGabriela Iwama
Gabriela Iwama
ASAnne-Kristin Solbakk
Anne-Kristin Solbakk
ABAlejandro O. Blenkmann
Alejandro O. Blenkmann
PLPal G. Larsson
Pal G. Larsson
RHRandolph Helfrich
Randolph Helfrich
The human prefrontal cortex (PFC) constitutes the structural basis underlying flexible cognitive control, where mixed-selective neural populations encode multiple task features to guide subsequent behavior. The mechanisms by which the brain simultaneously encodes multiple task–relevant variables while minimizing interference from task-irrelevant features remain unknown. Leveraging intracranial recordings from the human PFC, we first demonstrate that competition between coexisting representations of past and present task variables incurs a behavioral switch cost. Our results reveal that this interference between past and present states in the PFC is resolved through coding partitioning into distinct low-dimensional neural states; thereby strongly attenuating behavioral switch costs. In sum, these findings uncover a fundamental coding mechanism that constitutes a central building block of flexible cognitive control.

20 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
JWJan Weber
Jan Weber
ASAnne-Kristin Solbakk
Anne-Kristin Solbakk
ABAlejandro O. Blenkmann
Alejandro O. Blenkmann
ALAnais Llorens
Anais Llorens
IFIngrid Funderud
Ingrid Funderud
RHRandolph F. Helfrich
Randolph F. Helfrich
Contextual cues and prior evidence guide human goal-directed behavior. The neurophysiological mechanisms that implement contextual priors to guide subsequent actions in the human brain remain unclear. Using intracranial electroencephalography (iEEG), we demonstrate that increasing uncertainty introduces a shift from a purely oscillatory to a mixed processing regime with an additional ramping component. Oscillatory and ramping dynamics reflect dissociable signatures, which likely differentially contribute to the encoding and transfer of different cognitive variables in a cue-guided motor task. The results support the idea that prefrontal activity encodes rules and ensuing actions in distinct coding subspaces, while theta oscillations synchronize the prefrontal-motor network, possibly to guide action execution. Collectively, our results reveal how two key features of large-scale neural population activity, namely continuous ramping dynamics and oscillatory synchrony, jointly support rule-guided human behavior.

6 February 2024 in Epilepsia Open
Verified
Journal Article
Open access
KKKonstantin H. Kostov
Konstantin H. Kostov
HKHrisimir Kostov
Hrisimir Kostov
PLPål Gunnar Larsson
Pål Gunnar Larsson
OHOliver Henning
Oliver Henning
KAKari Modalsli Aaberg
Kari Modalsli Aaberg
MLMorten Ingvar Lossius
Morten Ingvar Lossius
Objective: Evaluate the long‐term efficacy of vagus nerve stimulation (VNS) in patients with developmental and epileptic encephalopathies (DEE) compared with epilepsy patients without intellectual disability (ID).Methods: Long‐term outcomes from a Norwegian VNS quality registry are reported in 105 patients with DEEs (Lennox–Gastaut syndrome [LGS] n = 62; Dravet n = 16; Rett n = 9; other syndromes n = 18) were compared with 212 epilepsy patients without ID, with median follow‐up of 88 and 72 months, respectively. Total seizure reduction was evaluated at 6, 12, 24, 36, and 60 months. Effect on different seizure types was evaluated at baseline and last observation carried forward (LOCF).Results: Median monthly seizure frequency at LOCF was reduced by 42.2% (p < 0.001) in patients with DEE and by 55.8% (p < 0.001) in patients without ID. In DEE patients, ≥50% seizure reduction at 6 and 24 months were 17.1% and 37.1%, respectively, and 33.5% and 48.6% for patients without ID. Seizure reduction ≥75% at 60 months occurred in 14.3% of DEE patients and 23.1% of patients without ID. Highest median reduction was for atonic seizures, most notably 64.6% for LGS patients. A better effect was seen at 2 years among DEE patients with unchanged medication compared with those with changed medication (54.5% vs. 35.6% responders, p = 0.078). More DEE patients were reported to have greater improvement in ictal or postictal severity (43.8% vs. 28.3%, p = 0.006) and alertness (62.9% vs. 31.6%, p < 0.001) than patients without ID. For both groups, use of the magnet reduced seizure severity. Hoarseness was the most common adverse effect in both groups. In addition, DEE patients were frequently reported to have sleep disturbance, general discomfort, or abdominal problems.Significance: Our data indicate that VNS is very effective for atonic seizures. Patients without ID had best overall seizure reduction, however, patients with DEE had higher retention rates probably due to other positive effects.Plain Language Summary: DEE refers to a group of patients with severe epilepsy and intellectual disability. Many of these patients have restricted lifestyles with frequent seizures. VNS is a treatment option for patients who do not respond well to medicines, either because of insufficient effect or serious adverse effects. Our study shows that VNS is well tolerated in this patient group and leads to a reduction in all seizure types, most notably for seizures leading to fall. Many patients experience other positive effects like shorter and milder seizures, as well as improvement in alertness.